

PFIZER INC  
Form 8-K  
September 03, 2004

OMB APPROVAL  
OMB Number: 3235-0060  
Expires: March 31, 2006  
Estimated average burden  
Hours per response .....28.0

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report: September 3, 2004  
Date of earliest event reported: September 3, 2004

**PFIZER INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other Jurisdiction of incorporation)

**1-3619**

(Commission File Number)

**13-5315170**

I.R.S. Employer  
Identification No.)

**235 East 42nd Street  
New York, New York**

(Address of principal executive  
offices)

**10017**

(Zip Code)

Registrant's telephone number, including area code:

(212) 573-2323

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On September 3, 2004, Pfizer Inc. (the "Company") issued a press release announcing that the Company and its wholly owned subsidiary, Quigley Company, Inc. ("Quigley"), (together, the "companies") have taken steps which, with court approval, will resolve all pending and future claims against the companies in which claimants allege personal injury from exposure to Quigley products containing asbestos, silica, or mixed dust. Quigley was acquired by Pfizer in 1968 and sold small amounts of products containing asbestos until the early 1970s.

Pfizer will take a charge of \$369 million before-tax (\$229 million after-tax) in the third quarter in connection with these matters. Quigley will file a Chapter 11 reorganization plan in the U.S. Bankruptcy Court for the Southern District of New York that must be approved by the court and confirmed by a vote of 75 percent of the claimants. In connection with that filing, Pfizer has entered into settlement agreements with lawyers representing more than 80 percent of the individuals with claims against the two companies that provide for a total of \$430 million in payments. The reorganization plan will establish a trust for the payment of all remaining pending claims as well as any future claims alleging injury from exposure to Quigley products. If approved by the court, the reorganization plan will result in a permanent injunction directing all future claims alleging personal injury from exposure to Quigley products to the Trust.

A copy of the press release, which includes further details about these matters, is attached as Exhibit 99 and is incorporated herein by reference.

Item 9.01(c). Exhibits

Exhibit 99 Press Release of Pfizer Inc. dated September 3, 2004.

**SIGNATURE**

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/Margaret M. Foran  
Margaret M. Foran  
Title: Vice President-Corporate  
Governance and Secretary

Dated: September 3, 2004

**EXHIBIT INDEX**

Exhibit No.	Description
99	Press Release of Pfizer Inc. dated September 3, 2004.